NOVARTIS GENE THERAPIES INC

Novartis Gene Therapies Inc. specializes in the manufacturing of pharmaceutical preparations, with a focus on advanced therapeutic products including hematological and gene-based treatments. The company leverages GMP-compliant production processes to develop and supply complex biologics and specialty drugs, ensuring strict adherence to FDA regulatory standards for purity, potency, and safety. Their technical expertise lies in aseptic manufacturing, lyophilization, cold chain logistics, and quality control systems tailored for high-value, low-volume therapeutics. As a manufacturer with deep domain knowledge in cell and gene therapy platforms, they bring precision scale-up capabilities and process validation rigor critical for clinical and commercial supply chains. The contractor has demonstrated direct engagement with the Department of Veterans Affairs, supplying drugs, pharmaceuticals, and hematology-related products under Federal Supply Schedule arrangements. This relationship reflects a trusted vendor status for specialized therapeutics used in veteran healthcare, particularly for chronic and rare disease management. Their work supports VA’s mission to deliver cutting-edge, evidence-based treatments through streamlined procurement channels. The primary NAICS code 325412 indicates a core focus on pharmaceutical preparation manufacturing, encompassing the formulation, filling, and packaging of active pharmaceutical ingredients into final dosage forms. The company’s market positioning centers on niche, high-complexity therapeutics, distinguishing itself through specialized manufacturing capabilities rather than broad-line drug distribution. Novartis Gene Therapies Inc. is structured as a 2L entity headquartered in Deerfield, Illinois. While no federal certifications are listed, their operations are governed by stringent pharmaceutical quality systems, including cGMP and ISO 13485 frameworks. Their geographic presence is anchored in a major biopharmaceutical hub, enabling proximity to regulatory bodies and clinical research networks critical to federal healthcare supply chains.